This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–3561.
Tam CS, Wierda WG, O’Brien S, Lerner S, Khouri IF, Kantarjian HM et al. Life after fludarabine, cyclophosphamide, & rituximab (FCR)—the clinical outcome of patients with chronic lymphocytic leukemia who receive salvage treatment after frontline FCR. Blood 2008; 112: 727.
Vellenga E, van Putten WL, van ‘t Veer MB, Zijlstra JM, Fibbe WE, van Oers MH et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 2008; 111: 537–543.
Moufarij MA, Sampath D, Keating MJ, Plunkett W . Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood 2006; 108: 4187–4193.
Majolino I, Ladetto M, Locasciulli A, Drandi D, Benedetti F, Gallamini A et al. High-risk fludarabine-pretreated B-cell chronic lymphocytic Leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission. Med Oncol 2006; 23: 359–368.
Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O’Brien S, Wen S et al. Phase I–II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2008; 26: 196–203.
Tsimberidou AM, Keating MJ . Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 2009; 115: 2824–2836.
Kaspers GJ, Veerman AJ, Pieters R, Van Zantwijk I, Hahlen K, van Wering ER . Drug combination testing in acute lymphoblastic leukemia using the MTT assay. Leuk Res 1995; 19: 175–181.
Acknowledgements
We thank GA Huls, MD PhD (University Medical Center, Groningen), S Hovenga, MD PhD (Nij Smellinghe Hospital, Drachten) and SH Wittebol, MD (Meander Medical Center, Amersfoort) for providing patient data. APK is personally supported by a ‘Veni’-grant from the Netherlands Organization for Health Research and Development.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tonino, S., van Gelder, M., Eldering, E. et al. R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia. Leukemia 24, 652–654 (2010). https://doi.org/10.1038/leu.2009.240
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2009.240
This article is cited by
-
Multiple drugs
Reactions Weekly (2018)
-
Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study
Bone Marrow Transplantation (2016)
-
The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1
Leukemia (2016)
-
ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia
Oncogene (2011)